Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03740490 · ClinicalTrials.gov registry record · Phase 2
Smartphone Based Smoking Cessation Intervention
A Phase 2 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 2
- Development phase
- 454
- Enrollment target
NCT03740490: Completed Phase 2 study, sponsored by University of Oklahoma.
NCT03740490 is a Phase 2 study that has completed, run by University of Oklahoma. The registered enrollment target is 454 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (241% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03740490, a Phase 2 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 454 participants
- Enrollment target
Study Summary
Smoking is becoming increasingly concentrated among individuals with the lowest levels of income, education, and occupational status. In fact, smoking rates in the United States among people living below the poverty line is nearly twice as high as those above the poverty threshold. Highly flexible and low burden technology-based treatment approaches may overcome many of the barriers that have limited the use and effectiveness of traditional smoking cessation treatments among low socioeconomic status (SES) adults. Ecological momentary assessment (EMA), in which mobile devices are used to capture moment-to-moment experiences, allows for the measurement of phenomena in real-time within natural settings. Smartphone-based smoking cessation apps could offer easily accessible, highly tailored, and intensive interventions at a fraction of the cost of traditional smoking cessation counseling. The Smart-T app uses a lapse risk estimator to identify moments of heightened risk for lapse, and the algorithm tailors treatment messages in real-time based upon level of imminent smoking lapse risk and currently present lapse triggers. This study will compare smoking cessation rates for those randomized to the Smart-T app or the NCI QuitGuide app.
Primary Outcome
Biochemically confirmed 7-day point prevalence abstinence using the CO criteria cutoff of ≤ 6 ppm
Interventions
- COMBINATION_PRODUCT QuitGuide + NRT
- COMBINATION_PRODUCT Smart-T + NRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 2 |
What the finished NCT03740490 record still lists
NCT03740490 is an interventional study that assigns participants to a tested intervention. The registered 454 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (241% higher).
The record links to 0 conditions, and to 2 interventions - of which QuitGuide + NRT is the first listed.
NCT03740490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03740490 about?
NCT03740490 is a clinical study titled "Smartphone Based Smoking Cessation Intervention". Smoking is becoming increasingly concentrated among individuals with the lowest levels of income, education, and occupational status. In fact, smoking rates in the United States among people living below the poverty line is nearly twice as high as those above the poverty threshold. Highly flexible a...
What is the current status of trial NCT03740490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 454 participants. The study started on 2019-08-26. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT03740490?
The interventions under investigation include: QuitGuide + NRT (COMBINATION_PRODUCT), Smart-T + NRT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03740490?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03740490's enrollment target sits among peer trials
454 87th of 2000 higher than 1,914 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05489211 · 454 participants · Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- NCT05655936 · 454 participants · NA
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
- NCT06510374 · 454 participants · Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
- NCT06935357 · 454 participants · Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI